Samuel Pine

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant <i>Mycobacterium tuberculosis</i>

Sylvie Bertholet, Gregory C. Ireton, Diane Ordway et al. · Science Translational Medicine · 2010 · 301 citations · Full text

Design and Conduct Considerations for First‐in‐Human Trials

Jie Shen, Brandon Swift, Richard D. Mamelok et al. · Clinical and Translational Science · 2018 · 171 citations · Full text

First‐in‐human Trials, Patient Selection, Pharmacotherapy +20

Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment

Rhea N. Coler, Sylvie Bertholet, Samuel Pine et al. · The Journal of Infectious Diseases · 2012 · 98 citations · Full text

Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals

Samuel Pine, M. Juliana McElrath, Pierre–Yves Bochud · AIDS · 2009 · 90 citations · Full text

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis

Evaldo Nascimento, Demetrios F. Fernandes, Edvá P. Vieira et al. · Vaccine · 2010 · 75 citations

Vaccination, Leish-f1+mpl-se Vaccine, Antiparasitic Agent +9